Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - An antibiotic produced by Streptomyces fradiae. [PubChem] (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| - 5.7 (± 2.8) hours. The elimination half-life is 40 hours in anuric patients undergoing hemodialysis. (en)
|
http://linked.open...ugbank/indication
| - For the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of <i>Escherichia coli</i> and <i>Enterococcus faecalis</i>. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Fosfomycin is a phosphoenolpyruvate analogue produced by Streptomyces that irreversibly inhibits enolpyruvate transferase (MurA), which prevents the formation of N-acetylmuramic acid, an essential element of the peptidoglycan cell wall. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...outeOfElimination
| - Fosfomycin is excreted unchanged in both urine and feces. (en)
|
http://linked.open.../drugbank/synonym
| - Fosfocina (en)
- Phosphomycin (en)
- Phosphonomycin (en)
- FOSFOMYCIN (en)
- (-)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid (en)
- (1R,2S)-Epoxypropylphosphonic acid (en)
- (2R-cis)-(3-Methyloxiranyl)phosphonic acid (en)
- 1R-cis-(1,2-Epoxypropyl)phosphonic acid (en)
- FCM (en)
- Fosfomicina (en)
- Fosfomycine (en)
- Fosfomycinum (en)
- L-cis-1,2-Epoxypropylphosphonic acid (en)
- Phosphonemycin (en)
- cis-(1R,2S)-Epoxypropylphosphonic acid (en)
|
http://linked.open...drugbank/toxicity
| - LD<sub>50</sub>>5 g/kg (rats). Side effects may include diarrhea (en)
|
http://linked.open...umeOfDistribution
| |
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...k/foodInteraction
| - Food decreases Cmax slightly. (en)
- Take without regard to meals. (en)
|
http://linked.open...nk/proteinBinding
| - 0% (not bound to plasma proteins) (en)
|
http://linked.open...ogy/drugbank/salt
| |
http://linked.open...ynthesisReference
| - Graziano Castaldi, Claudio Giordano, "Process for the preparation of intermediates for the synthesis of fosfomycin." U.S. Patent US4937367, issued March, 1972. (en)
|
http://linked.open...y/mesh/hasConcept
| |
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Fosfomycin tromethamine is rapidly absorbed following oral administration and converted to fosfomycin. Oral bioavailability under fasting conditions is 37%. When given with food, oral bioavailability is reduced to 30% (en)
|
http://linked.open.../affectedOrganism
| - Enteric bacteria and other eubacteria (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...rugbank/clearance
| |
http://linked.open...gbank/containedIn
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...ank/Melting-Point
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...strongest-acidic-
| |
http://linked.open...-strongest-basic-
| |